Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR‐T cell therapy in KMT2A‐rearranged, therapy‐related acute lymphoblastic leukemia

Abstract

Palbociclib induces leukemia cell senescence by permanent G0/G1 cell cycle arrest. Blinatumomab is a bispecific T-cell engager that binds CD3 T cells and CD19 leukemia B cells subjecting cells to T-cell mediated cytotoxicity. (B) CDK4 interacts with cyclin D to promote cell cycle progression. (C) KMT2Ar cells rely on CDK6 to maintain an immature phenotype. By targeting CDK4/6, cells are unable to enter the synthesis phase of the cell cycle.